Additionally, rendering T cells insensitive to Fgl2 binding through FcγRIIB by engineering Fcgr2b–/– tumor-infiltrating lymphocyte or CAR-T therapies may preserve high-quality T cells important to the antitumor response. Here, FGL2 is linked to neoplasm.